Attached files

file filename
EX-99.1 - EX-99.1 - ZS Pharma, Inc.d933000dex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 28, 2015 (May 28, 2015)

 

 

ZS Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36489   26-3305698

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

805 Veterans Blvd., Suite 300

Redwood City, CA

  94063
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 458-4100

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On May 28, 2015, ZS Pharma, Inc. (the “Company”) issued a press release announcing that the Company will participate in the Jefferies 2015 Global Healthcare Conference on June 2, 2015 in New York, New York and the William Blair 35th Annual Growth Stock Conference on June 9, 2015 in Chicago, Illinois. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

EXHIBIT
NUMBER

  

DESCRIPTION

99.1    Press Release, dated May 28, 2015


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ZS PHARMA, INC.
Date: May 28, 2015 By:

/s/ Todd Creech

Todd Creech
Chief Financial Officer


INDEX TO EXHIBITS

 

EXHIBIT
NUMBER

  

DESCRIPTION

99.1    Press Release, dated May 28, 2015